Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Jazz Pharmaceuticals (JAZZ) reported $901.98 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 1%. EPS of $2.68 for the same period compares to $3.95 a year ago.The reported revenue represents a surprise of -3.94% over the Zacks Consensus Estimate of $938.99 million. With the consensus EPS estimate being $4.14, the EPS surprise was -35.27%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...